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Inherited thrombocytopenias are associated with bleeding of all types of severity depending 
on the reduction in platelet count and whether there is altered platelet function.1 The normal 
range for platelet counts varies by up to threefold, but an individual’s platelet count is 
normally maintained within a narrow range. This requires a constant balance between 
thrombopoiesis, and platelet senescence and consumption. Heritable forms of 
thrombocytopenia are frequently caused by genes which regulate megakaryocytic 
differentiation and/or platelet production. Next generation sequencing strategies, such as 
whole exome sequencing, are efficient in identifying gene mutations that cause Mendelian 
disorders.2-4 In this study, we used a whole exome-sequencing approach, to elucidate the 
genetic basis of a severe form of congenital thrombocytopenia.  
 
We present a UK consanguineous family of Pakistani origin with two cousins with severe 
thrombocytopenia (Figure 1B). The proband, III:5, was aged three years with a platelet count 
of 3x109/l when entered into the Genotyping and Phenotyping of Platelets (GAPP) study. He 
was born by emergency caesarean section at 34 weeks gestation and had neurological 
symptoms shortly after birth and bilateral intraventricular haemorrhages. He had a 
ventriculo-peritoneal shunt inserted which required several revisions, with HLA platelet 
transfusion prophylaxis. He has developmental delay, skull abnormalities secondary to 
hydrocephalus and nystagmus. His baseline platelet count has remained at approximately 
10 x 109/l. He received HLA matched platelet transfusions every 1-2 weeks for the first 
twelve months of life and his platelet count incremented well hereafter. There are no other 
abnormalities in the blood count. The bone marrow aspirate and trephine showed a 
normocellular specimen with normal megakaryocyte numbers and morphology and normal 
cytogenetics. Patient III:3 was aged seven years when recruited into the study. She has a 
baseline platelet count of 15-20 x 109/l and receives weekly HLA matched platelet 
transfusions to minimize symptoms from epistaxis and haematomata, previously causing 
hospitalisation. In both patients, coagulation parameters were normal and there were no 
anti-platelet autoantibodies or HLA antibodies. Blood (15 ml) from patients and healthy 
controls was taken in 10% by volume 3.8% trisodium citrate. Platelet rich plasma (PRP) was 
prepared and flow cytometry was conducted as previously described.5 Transmission electron 
microscopy was performed as described6 and examined using a JEOL 1200EX transmission 
electron microscope (Hertfordshire, UK). The number of α-granules per µm2 was calculated 
for at least 40 platelets from each patient/control. The whole exome of the two affected 
individuals was sequenced with the SureSelect human All Exon 50Mb kit (Agilent 
Technologies) and sequencing on the HiSeq 2000 (Illumina) with 100 bp paired-end reads. 
The sequences were aligned to the reference genome (hg19 build).5 To verify candidate 
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mutations, Sanger sequencing was performed using standard methods on an ABI 3730 
automated sequencer.  
 
Both patients have severe thrombocytopenia with platelet counts in platelet rich plasma 
(PRP) of :- patient III:5 1.5 x 107/ml and patient III:3 2.5 x 107/ml, reference range 2.1-7.1 x 
108/ml [mean±2s.d.]. Mean platelet volume in patient III:5 and III:3 was 15.0fl and 10.4fl 
respectively (reference range 7.68-10.0fl). Parental platelet counts were normal. An 
extremely high Immature Platelet Fraction (IPF) of 87 and 83% (normal range 1.3-10.8%, 
n=40) was found in patients III:5 and III:3 respectively which suggests rapid production 
(possibly due to rapid clearance). Flow cytometry was used to assess platelet function in the 
two affected individuals, using an assay validated for activated platelets using dilutions of 
PRP from healthy volunteers. The levels of surface glycoproteins CD42b (GPIbα), CD41 
(αIIb) and GPVI in patient III:3 were within the reference ranges established in healthy 
volunteers, whereas for patient III:5, the levels of CD42b and CD41 fell outside. This could 
suggest global platelet dysfunction, where loss of glycans can lead to failure of the receptor 
being transported to the surface, or to increased proteolysis (Figure 2A). Patient III:5 also 
showed a complete abolition of CD62P (P-selectin) expression and a very weak increase in 
binding of fibrinogen to ADP, CRP and PAR-1 (Figure 2B and 2C). Patient III:3 showed a 
slightly greater increase in fibrinogen binding than III:5 to most agonists and a recovery of 
CD62P expression to high concentrations of CRP and PAR1 peptide, although this was 
below the range of responses to healthy controls in all cases. Electron microscopy of patient 
platelets revealed that these are enlarged but with a similar number of α-granules per 
surface area, compared to controls (Figure 2D).  
 
The exome of both patients was sequenced and the alignment of the sequencing reads 
revealed 23,943 and 24,293 variations in patients III:3 and III:5 respectively. Comparisons 
within the EVS, 1000G and our in house GAPP database of over 1200 exomes identified two 
homozygous non-synonymous variants and 1 non-frameshift deletion that were present in 
both patients (Supplementary Tables 1 and  2), with all variations mapping to a tightly-linked 
homozygous region on chromosome 9p13.3 (Supplementary Table 2). The two non-
synonymous variants were in genes GNE (p.G416R) and FRMPD1 (p.A509V) and the non-
frameshift deletion in ANKRD18A (p.Glu801del). Family studies using Sanger sequencing 
confirmed that all three variants segregated with disease status (Figure 1B). Pathogenicity 
was predicted using four separate in silico based pathogenicity prediction softwares 
(MutationTaster, SIFT, PROVEAN and PolyPhen-2) and conservation at the site of variation 
was determined by PhyloP and PhastCons. Together all three variants were classified as 
“unknown significance” when considering the ACMG consensus guidelines. Upon further 
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analysis within the ExAC database, only the variants within ANKRD18A and GNE were 
novel. Data from RNA sequencing of hematopoietic progenitors (blueprint.haem.cam.ac.uk), 
suggested that there was very low expression of ANKRD18A mRNA in hematopoietic 
progenitors. This is in contrast to GNE mRNA, which is expressed widely in hematopoietic 
progenitors.  
 
In previous studies, two compound heterozygous variations in the gene encoding GNE have 
been noted to cause a disorder of progressive muscle weakness with a secondary symptom 
of thrombocytopenia.7 8  Previous dominant mutations in GNE have been associated with 
sialuria.9 10 It is important to note that the recessive patients presented with severe body 
myopathy as a primary symptom, while the patients in our study do not display signs of 
myopathy although this is possibly because of their age. Furthermore a previous study 
involving the whole exome sequencing of a single pedigree with severe thrombocytopenia 
and bleeding identified an apparent PRKACG variant but a strong candidate variant in this 
family was also a homozygous missense variant in the kinase domain of GNE (p.G559R) as 
shown in Figure 1C.11   
GNE encodes Glucosamine (UDP-N-Acetyl)-2-Epimerase/N-acetylmannosamine kinase, a 
bi-functional enzyme involved in the sialic acid biosynthesis pathway and is expressed within 
all cells of the haematopoietic lineage. Thrombocytopenia is known to be associated with 
increased platelet desialylation in septic patients due to altered platelet production/survival.12  
Further, platelet counts are increased in a cohort of influenza patients treated with the 
sialidase inhibitor, oseltamivir (Tamiflu).13  A platelet clearance system has been shown to 
exist for desialylated platelets involving macrophages and hepatocytes.14 The Ashwell-Morell 
receptor binds platelets with reduced sialic acid expression15 and removal of just 8-10% of 
sialic acid residues by neuraminidase treatment leads to increased platelet clearance rates 
in vivo.16  
In summary, our results indicate that the GNE mutation described here leads 
to macrothrombocytopenia, possibly due to a reduction in sialic acid biosynthesis, which is 
expected to cause increased removal of platelets and altered platelet formation.   
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Figures 
Figure 1. Identification of a homozygous missense substitution in GNE. (A) Filtering 
strategy of whole exome sequencing results to identify candidate variants in patients III:3 
and III:5 of the same family. (B) Segregation analysis of the exome candidates in family 
members where DNA was available.  The three variants (in the genes GNE, FRMPD1 and 
ANKRD18A) were shared by both children and were located within a region of homozygosity 
on chromosome 9p13.3.  Double lines linking parents signify first cousin unions. (C) Linear 
domain organisation of GNE encoding the enzyme UDP-GlcNAc 2-epimerase/ManNAc 
kinase. Experimental allosteric sites are based on in vitro studies (AS), region of unknown 
function (UF). The approximate position of amino acid substitutions (p.G416R and p.G559R) 
found in the family in this study and in an independent study11 respectively are indicated and 
based on transcript NM_005476. 
 
Figure 2. Flow cytometry and transmission electron microscopy assessment of 
platelet function in patients III:3 and III:5. Flow cytometry assessment of platelet function 
in patients III:3 and III:5 assessed on Accuri C6 flow cytometer.  (A) Platelet glycoprotein 
receptors. (B)  CD62P expression and (C) fluorescent fibrinogen binding following platelet 
stimulation by various agonists for 2 min.  The platelet rich plasma from healthy controls was 
diluted 1 in 10 with phosphate buffered saline and served as a control range.   Data for 
healthy volunteers shown as mean + 1 s.d. (n= 9, except for GPVI where n=2)). (D) 
Transmission electron microscopy image of the platelets from patient III:5 and a healthy 
control platelets. Arrow indicates α granule, graph shows number of alpha granules/surface 
area, scale bar = 2µm. 
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